Related Experiment Video
Updated: Jun 3, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Prophylaxis for inherited factor X deficiency: a systematic review.
Vitor José Poletto Ferreira1, Alessandra Fatima da Costa1, Renan Pedra Souza2,3
1Faculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Prophylaxis for hereditary factor X deficiency (FXD) shows promise in reducing bleeds compared to on-demand treatment. However, further high-quality research is essential to confirm these findings for people with FXD.
Area of Science:
- Hematology
- Pharmacology
- Clinical Trials
Background:
- Hereditary factor X deficiency (FXD) necessitates treatment to manage or prevent bleeding episodes.
- Current therapies involve episodic (on-demand) treatment or prophylactic administration of procoagulants.
Conclusions:
- Prophylaxis appears more effective in reducing bleeding events for people with FXD than on-demand treatment.
- The current evidence base is largely derived from low-to-intermediate quality studies, necessitating further investigation.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Factors Affecting Drug Response: Overview
Pharmacogenomics: Identification of New Drug Targets
Venous Thrombosis IV: Nursing Management
